MARKET

BMRN

BMRN

BioMarin Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

78.60
-0.70
-0.88%
After Hours: 78.60 0 0.00% 16:28 09/24 EDT
OPEN
79.10
PREV CLOSE
79.30
HIGH
79.41
LOW
78.34
VOLUME
463.16K
TURNOVER
--
52 WEEK HIGH
92.57
52 WEEK LOW
71.65
MARKET CAP
14.41B
P/E (TTM)
-584.8214
1D
5D
1M
3M
1Y
5Y
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Benzinga · 09/09 19:23
Stifel Upgrades Biomarin Pharmaceutical to Buy, Raises Price Target to $96
Stifel analyst Paul Matteis upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Hold to Buy and raises the price target from $86 to $96.
Benzinga · 09/09 10:50
Stifel Upgrades BioMarin Pharmaceutical to Buy from Hold, Adjusts Price Target to $96 from $86
MT Newswires · 09/09 07:53
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
Zacks.com · 09/08 15:39
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
AmericaNewsHour · 09/08 06:26
Hot Stocks: AMC leads theater stocks; NFLX price target; ADAP gets partnership; MRCY sets new low; FDA hold for BMRN
It might have been a mixed day for the broader averages, but AMC Entertainment (NYSE:AMC) had an unambiguously good session. No, this wasn't a result of meme-stock traders attempting to force
Seekingalpha · 09/07 21:30
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
Zacks.com · 09/07 14:08
Price To Earnings Ratio Insights For Biomarin Pharmaceutical
 
Benzinga · 09/07 13:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMRN. Analyze the recent business situations of BioMarin Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMRN stock price target is 110.83 with a high estimate of 165.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 754
Institutional Holdings: 188.03M
% Owned: 102.55%
Shares Outstanding: 183.35M
TypeInstitutionsShares
Increased
175
6.28M
New
53
946.63K
Decreased
176
7.77M
Sold Out
53
1.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/Director
Jean-Jacques Bienaime
Chief Financial Officer/Executive Vice President
Brian Mueller
Corporate Executive
Henry Fuchs
Executive Vice President/Chief Technology Officer
C. Greg Guyer
Executive Vice President/General Counsel/Secretary
G. Eric Davis
Executive Vice President
Jeff Ajer
Chief Accounting Officer/Vice President
Andrea Acosta
Lead Director/Independent Director
Richard Meier
Independent Director
Elizabeth Anderson
Independent Director
Willard Dere
Independent Director
Elaine Heron
Independent Director
Maykin Ho
Independent Director
Robert Hombach
Independent Director
V. Bryan Lawlis
Independent Director
David Pyott
Independent Director
Dennis Slamon
No Data
  • All
  • Financials
  • Insiders
More
About BMRN
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Webull offers kinds of BioMarin Pharmaceutical Inc. stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.